ENDPOINTS

Bristol Myers' MyoKardia unit ends work with Fulcrum; A...

Plus, news about Tenax Therapeutics and Celon Pharma: Fulcrum Therapeutics l...

FDA puts BioNTech’s malaria vaccine on clinical hold

BioNTech has paused an early-stage study of its experimental malaria vaccine aft...

 FDA puts BioNTech’s malaria vaccine on clinical hold

BioNTech has paused an early-stage study of its experimental malaria vaccine aft...

Bhattacharya hearing updates: Trump NIH nominee faces S...

Trump's NIH nominee Jayanta "Jay" Bhattacharya goes before a Senate committee on...

Jazz to buy Chimerix for $935M to get brain tumor drug ...

Jazz Pharmaceuticals will buy North Carolina biotech Chimerix for $935 million i...

Bayer cautions pharma sales dip this year despite major...

Bayer said Wednesday its pharmaceuticals unit will likely see a decline in sales...

Eli Lilly seeks pitches from US states for slice of $27...

Eli Lilly is doing something out of the box to find where it would pour its late...

Persica shares early data for antibiotic in chronic bac...

Persica Pharmaceuticals said it has promising Phase 1b results that support its ...

China bans imports of Illumina's DNA sequencers followi...

China will ban the import of DNA sequencers from San Diego-based Illumina, an ap...

China to ban Illumina's DNA sequencers following US tar...

China will ban the import of DNA sequencers from San Diego-based Illumina, an ap...

Misleading promotion lands NJ drugmaker a letter from FDA

Edenbridge Pharmaceuticals received this year's first untitled letter from the F...

Teladoc holds out for 2026

Teladoc is in a rebuilding era. Once a stock market darling during the pande...

DOGE shutters lease on FDA lab in St. Louis and 29 othe...

The Department of Government Efficiency says that it has terminated the leases o...

At least eight drugmakers say they will participate in ...

More than half of drugmakers have agreed to participate in the second round of M...

PepGen delays study for Duchenne drug as it awaits safe...

PepGen is "temporarily pausing" a Phase 2 study of its exon 51 skipping drug for...

Swiss biotech ends Phase 2 study in Alzheimer's shortly...

A small Swiss biotech has terminated a mid-stage test of a new type of oral drug...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.